TNFRSF9 and head and neck squamous cell carcinoma: We recently demonstrated that the amount of circulating CD137+ T cells had a predictive and prognostic role in survival in advanced head and neck squamous cell carcinoma (HNSCC) patients treated with pembrolizumab as first-line therapy [15].